Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.
Also called NCT02932436
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 144 participants
- Registry
-
NCT02932436 -
2016-001264-11
-
- Other papers using this trial's data
- Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial
- Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02932436. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-10 (actual); primary completion 2020-06-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
- Acronym
- EmDia
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diastolic Dysfunction
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Johannes Gutenberg University Mainz
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02932436- Content hash
2c456aa51df8710cd7abe6d826d9b0393f9c95577ca8358bfa96d5b2fc25c1e0